Corona Remedies opened at ₹2,015.00, in line with its previous close of ₹2,015.30. During today's session, the stock has traded between ₹1,941.50 and ₹2,030.90, with an average traded price of ₹1,988.39. It is currently showing a sideways intraday trend.
An investment of ₹10,000 made 1 year ago in Corona Remedies is now worth
₹ 14,086.00
giving a profit of
₹ 4,086.00 (40.86%)
Note: Past profits do not guarantee future returns.
No analyst rating data available.
Today's Change
+10.90 (+0.54%)
Day High
₹2,030.90
Day Low
₹1,941.50
Day Open
₹2,015.00
Prev Close
₹2,015.30
Volume
21,997
Value Traded
₹4.37 Cr
1W Return
-0.39%
1M Return
-9.39%
3M Return
-0.81%
6M Return
29.51%
1Y Return
40.86%
Market Cap (₹ Cr.)
12,392
PE Ratio
61.90
PB Ratio
16.49
Dividend Yield
0.50%
ROE
24.79%
ROCE
29.31%
Book Value (₹)
122.12
Face Value (₹)
10.00
EPS (TTM)
9.83
Industry PE
-
Beta
-
Debt to Equity
-
1 Week
-0.39%
6 Week
-
1 Month
-9.39%
3 Month
-0.81%
9 Month
44.70%
Sepia, Sage, Anchor sell 2.63m Corona Remedies shares under SAST
Sepia Investments, Sage Investment Trust, and Anchor Partners sold 2.63 million shares. Sales occurred via open market on NSE on September 10, 2026. Disclosure filed under SEBI SAST Regulations 29(2). Sepia's stake reduced from 12.68% to 8.62%. Sellers are identified as persons acting in concert.
24 days agoCorona Remedies to host JP Morgan-led analyst meet on Sep 23
Corona Remedies to hold analyst meet on Sep 23, 2026. Session organized by JP Morgan in Ahmedabad at 2:00 pm. Discussions limited to publicly available information. No unpublished price-sensitive information to be shared.
25 days agoCorona Remedies to hold analyst and investor meeting on August 26
Corona Remedies to host analyst and investor meeting on August 26. Event organized by Phillip Capital PCG in Ahmedabad. Discussions limited to publicly available information only. No UPSI will be discussed per SEBI regulations.
1mo agoCorona Remedies officials to attend Emkay, Equirus investor meets in Mumbai
Corona Remedies Limited has announced that its officials will attend investor conferences organized by Emkay Global and Equirus in Mumbai on August 13 and 14, 2026. The meetings will be conducted in-person and will cover group and one-on-one sessions. The company emphasized that discussions will be restricted to publicly available information, ensuring compliance with SEBI's LODR Regulations.
2mo agoCorona Remedies Q1 Results: Earnings call audio now available online
Corona Remedies Limited disclosed the availability of its Q1 FY27 earnings call audio on August 3, 2026. The recording, hosted on the company website, details management's discussion on the unaudited results for the quarter ended June 30, 2026, in compliance with SEBI Regulation 30.
2mo agoCorona Remedies Q1FY27 Net Profit Rises 30.1% to ₹60.1 Cr on Revenue Surge
Corona Remedies reported strong Q1FY27 results with net profit rising 30.1% YoY to ₹60.1 crore and revenue growing 21.9% to ₹422.4 crore. EBITDA stood at ₹93.0 crore with margin expanding to 22.04% from 20.49%, while the company climbed to 26th rank in the India Prescription Market and inaugurated its EU-GMP approved Female Hormone Manufacturing Facility in Ahmedabad.
2mo ago| Stock | LTP | Change % | Market Cap (Cr.) | PE | 1Y Return |
|---|---|---|---|---|---|
| ₹1,770.70 | +0.61% | ₹4,24,850.24 | 34.83 | +5.97% | |
| ₹9,285.00 | -1.50% | ₹2,46,487.58 | 85.12 | +43.41% | |
| ₹4,642.90 | -0.84% | ₹1,76,600.99 | 82.55 | +31.42% | |
| ₹1,132.50 | -0.17% | ₹1,12,967.31 | 24.74 | +14.00% | |
| ₹2,059.40 | -0.47% | ₹1,11,271.90 | 102.63 | +134.89% | |
| ₹1,329.60 | +1.40% | ₹1,07,412.86 | 31.62 | -14.87% | |
| ₹1,240.00 | +0.86% | ₹1,03,500.36 | 32.26 | -1.93% | |
| ₹2,372.00 | -1.17% | ₹97,974.30 | 47.92 | -3.57% | |
| ₹1,684.60 | -1.31% | ₹96,928.16 | 26.40 | +49.04% | |
| ₹1,953.60 | +0.96% | ₹89,336.17 | 16.03 | -0.29% | |
| ₹2,265.30 | -0.78% | ₹63,932.35 | 35.82 | +16.81% | |
| ₹5,250.00 | +0.86% | ₹62,771.63 | 28.34 | -3.75% |
An investment of ₹10,000 made 1 year ago in Corona Remedies is now worth
₹ 14,086.00
giving a profit of
₹ 4,086.00 (40.86%)
Note: Past profits do not guarantee future returns.
